Steris Plc (NYSE:STE) Stake Increased by Great West Life Assurance Co. Can
Great West Life Assurance Co. Can boosted its stake in Steris Plc (NYSE:STE) by 3.9% during the second quarter, Holdings Channel reports. The institutional investor owned 134,861 shares of the medical equipment provider’s stock after buying an additional 5,077 shares during the period. Great West Life Assurance Co. Can’s holdings in Steris Plc were worth $10,964,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Harbour Capital Advisors LLC purchased a new position in shares of Steris Plc during the second quarter valued at about $3,750,000. Boston Financial Mangement LLC purchased a new position in shares of Steris Plc during the second quarter valued at about $9,252,000. Benjamin F. Edwards & Company Inc. boosted its position in shares of Steris Plc by 3.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 9,550 shares of the medical equipment provider’s stock valued at $778,000 after buying an additional 318 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Steris Plc by 12.1% in the second quarter. Russell Investments Group Ltd. now owns 148,026 shares of the medical equipment provider’s stock valued at $12,064,000 after buying an additional 15,991 shares in the last quarter. Finally, Copeland Capital Management LLC boosted its position in shares of Steris Plc by 11.5% in the second quarter. Copeland Capital Management LLC now owns 396,393 shares of the medical equipment provider’s stock valued at $32,306,000 after buying an additional 40,954 shares in the last quarter. Hedge funds and other institutional investors own 91.80% of the company’s stock.
Shares of Steris Plc (NYSE:STE) opened at 86.23 on Thursday. Steris Plc has a 52 week low of $63.80 and a 52 week high of $87.49. The company has a 50-day moving average price of $82.41 and a 200-day moving average price of $74.89. The stock has a market cap of $7.33 billion, a price-to-earnings ratio of 67.37 and a beta of 1.33.
Steris Plc (NYSE:STE) last announced its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported $0.85 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.80 by $0.05. The company had revenue of $608 million for the quarter, compared to the consensus estimate of $597.66 million. Steris Plc had a return on equity of 11.12% and a net margin of 4.20%. Steris Plc’s quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.79 EPS. Equities analysts anticipate that Steris Plc will post $4.04 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Tuesday, August 29th will be given a $0.31 dividend. This represents a $1.24 annualized dividend and a yield of 1.44%. The ex-dividend date is Friday, August 25th. This is an increase from Steris Plc’s previous quarterly dividend of $0.28. Steris Plc’s dividend payout ratio is 87.50%.
Several brokerages have recently issued reports on STE. Raymond James Financial, Inc. raised their target price on shares of Steris Plc from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday. BidaskClub cut shares of Steris Plc from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research upgraded shares of Steris Plc from a “hold” rating to a “buy” rating and set a $92.00 target price on the stock in a report on Tuesday, July 11th. Wellington Shields cut shares of Steris Plc from a “gradually accumulate” rating to a “hold” rating in a report on Monday, June 5th. Finally, KeyCorp upgraded shares of Steris Plc from a “sector weight” rating to an “overweight” rating and set a $89.00 target price on the stock in a report on Wednesday, May 3rd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $86.75.
In other Steris Plc news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the company’s stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $80.05, for a total value of $800,500.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Sudhir K. Pahwa sold 800 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $77.28, for a total value of $61,824.00. The disclosure for this sale can be found here. Insiders sold a total of 30,340 shares of company stock worth $2,432,704 in the last ninety days. 2.55% of the stock is currently owned by corporate insiders.
About Steris Plc
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris Plc (NYSE:STE).
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.